TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00475410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASCs (Cx401, company code)
Description: Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASCs (Cx401, company code)
Description: Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin adhesive
Description: Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin adhesive
Description: Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
Study: NCT01080820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX157
Description: One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viread
Description: One single oral dose of 300mg Viread.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viread
Description: One single oral dose of 300mg Viread.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread
Description: One single oral dose of 300mg Viread.
Study: NCT00198133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premetrexed (Alimta)
Description: Pemetrexed will be 500 mg/m2 IV every 3 weeks
Study: NCT00160524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (CDP870)
Description: Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
Study: NCT03425019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix 1x1 tDCS mini-CT Stimulator device
Description: Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
Study: NCT03291795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Study patients will undergo a program of prehabilitation exercise for 6 days per week prescribed for them by an exercise physiologist, for up to 4 weeks prior to surgery.
Study: NCT02518906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Identity Treatment
Description: Integrative Approach for the treatment of adolescents with Personality Disorder.~Manual was published in 2013.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-A
Description: Dialectic Behavioral Treatment for Adolescents is the most commonly used Approach for the Treatment of adolescents with Boderline Personality Disorder
Study: NCT01342653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC
Description: see Design
Study: NCT03490890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microwave ablaton
Description: Patients with pathology verified GGO were treated with MWA.
Study: NCT02980679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTC
Description: After injection of CTC, a whole body and thyroid scan will be performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-PERT
Description: After injection of G-PERT, a whole body and thyroid scan will be performed.
Study: NCT02537444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib and pembrolizumab combination
Study: NCT04185610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qi Gong
Description: Guided Qi Gong class
Study: NCT03306069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based high-intensity interval training (HIIT).~HIIT:~* 2 sessions per week~* 5x1 min at 80-95% HRmax~* time-effort per week: \~30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIIT-HR
Description: Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of HRmax (MIIT-HR).~MIIT-HR:~* 2 sessions per week~* 5x1 min at 65-79% HRmax~* time-effort per week: \~30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIIT-LT
Description: Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of lactate threshold (MIIT-LT).~MIIT-LT:~* 2 sessions per week~* session 1: 2x4 min / session 2: 5x1 min, each at 105% LT~* time-effort per week: \~30 min
Study: NCT02341014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: The initial dose of carfilzomib (cycle 1, day 1) given to any patient must be 20mg/m2 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT02807454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04490668

Intervention type: BIOLOGICAL
Intervention: Human albumin
Description: Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.

Intervention type: BIOLOGICAL
Intervention: Human albumin
Description: Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
Study: NCT01772342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEPA filtration
Description: Night time air purification with the PureNight air purification system with the HEPA filter in place

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Night time air purification with the PureNight air purification system with the HEPA filter removed
Study: NCT01074411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02222727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
Study: NCT03774745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mifepristone 200 MG
Description: All subjects receive mifepristone tablet on treatment day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 MG
Description: All subjects receive mifepristone tablet on treatment day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized Progesterone
Description: Subjects randomized to progesterone receive treatment starting day 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Subjects randomized to placebo receive treatment starting day 2.
Study: NCT02009137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVERA
Description: EVERA apply for 12 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESTES
Description: ESTES apply for 12 weeks
Study: NCT02350894

Intervention type: BEHAVIORAL
Intervention: Graded and behavevial theraphy
Description: Graded and behavevial theraphy
Study: NCT01025180

Intervention type: OTHER
Group type: OTHER
Intervention: Procalcitonin level
Description: The duration of antibiotic treatment is based on PCT level:~* \< 0.25 ng/ml: antibiotic should be stopped~* 0.25 \< PCT \<0.5: antibiotic prescription is not recommended~* \> 0.5 ng/ml: antibiotic should be used
Study: NCT01247818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (0.002% Rose Bengal)
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (0.005% Rose Bengal)
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (0.01% Rose Bengal)
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study: NCT02742649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Combination
Description: Continuous elution from the ocular insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Continuous elution from the ocular insert. This is an active control arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Continuous elution from the ocular insert. This is an active control arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Segment
Description: One segment of placebo (no drug product)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Segment
Description: One segment of placebo (no drug product)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Segment
Description: One segment of placebo (no drug product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Description: 0.5% timolol drops twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Description: 0.5% timolol drops twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Description: 0.5% timolol drops twice daily.
Study: NCT01959867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurgiMend® PRS
Description: Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
Study: NCT01465737

Intervention type: OTHER
Intervention: Histologic types
Description: evaluate survival among different histologic types
Study: NCT01666236

Intervention type: OTHER
Group type: OTHER
Intervention: Triple Therapy
Description: The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light \[wavelength of 689 nm\] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections
Study: NCT02666534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine-prilocaine 5% cream application
Description: The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl-aminolevulinate application
Description: Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl-aminolevulinate application
Description: Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illuminating using red light-emitting diode lamps
Description: Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Illuminating using red light-emitting diode lamps
Description: Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
Study: NCT04948567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: split-dose of Magnesium Sulfate solution
Description: purgative for bowel preparation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: split-dose of PEG
Description: purgative for bowel preparation
Study: NCT00881478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition counseling + portion control tool
Description: Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition counseling
Description: Nutrition counseling with registered dietician
Study: NCT03759288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab low dose
Description: Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab low dose
Description: Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab high dose
Description: Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab high dose
Description: Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira®
Description: Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
Study: NCT02382601

Intervention type: RADIATION
Intervention: Ultrasound
Description: With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.

Intervention type: RADIATION
Intervention: Ultrasound
Description: With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.

Intervention type: RADIATION
Intervention: MRI
Description: Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.

Intervention type: RADIATION
Intervention: MRI
Description: Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.

Intervention type: PROCEDURE
Intervention: Blood collection
Description: The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.

Intervention type: PROCEDURE
Intervention: Blood collection
Description: The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.

Intervention type: BEHAVIORAL
Intervention: Neurological Function Assessment
Description: Neurological development tests including a Bayley exam, Mullen exam, Developmental Profile-3, Child Behavior Checklist, and Pediatric Stroke Outcome Measure (PSOM) will be performed.

Intervention type: BEHAVIORAL
Intervention: Neurological Function Assessment
Description: Neurological development tests including a Bayley exam, Mullen exam, Developmental Profile-3, Child Behavior Checklist, and Pediatric Stroke Outcome Measure (PSOM) will be performed.
Study: NCT00409240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEDIC
Description: Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction (MEDIC; a pharmacist-led behavioral and pharmacologic intervention in groups.
Study: NCT03261635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Injection
Description: patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection
Description: patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months
Study: NCT06204523

Intervention type: DIAGNOSTIC_TEST
Intervention: investigated biomarkers regarding the efficacy of first-line chemotherapy
Description: The present study was designed to generate solid evidence on the predictivity of the investigated biomarkers regarding the efficacy of first-line chemotherapy in patients with GC
Study: NCT02818816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine tartrate 0.2%
Description: Alpha adrenergic receptor agonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carboxymethylcellulose Eye Drops
Description: Ocular lubricants
Study: NCT02382601

Intervention type: PROCEDURE
Intervention: Placental Analysis
Description: Placentas will undergo pathological evaluation for placental function.

Intervention type: PROCEDURE
Intervention: Placental Analysis
Description: Placentas will undergo pathological evaluation for placental function.

Intervention type: PROCEDURE
Intervention: Measurement of body fat
Description: The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.

Intervention type: PROCEDURE
Intervention: Measurement of body fat
Description: The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.

Intervention type: RADIATION
Intervention: Pediatric heart ultrasound
Description: Children will have ultrasounds of their hearts during follow-up visits.